Minerva Neurosciences reports positive phase I data with MIN-202

Minerva Neurosciences, announced that preliminary results from a Phase 1 clinical study showed that treatment with MIN-202, a selective orexin-2 antagonist, resulted in significant improvements in sleep onset and sleep duration in patients with comorbid insomnia related to major depressive disorder (MDD).

Category One, Showcase, status, Uncategorized, What's Hot